Hostname: page-component-77c89778f8-cnmwb Total loading time: 0 Render date: 2024-07-17T17:00:46.671Z Has data issue: false hasContentIssue false
  • English
  • Français

Pre-clinical Pharmacology of Moclobemide

A Review of Published Studies

Published online by Cambridge University Press:  06 August 2018

Willy Haefely ,
Mosé da Prada ,
Rolf Kettler ,
Hans H. Keller  and
Willy P. Burkard
Willy Haefely
Affiliation:
F. Hoffman-La Roche Ltd, Basel, Switzerland
Mosé da Prada
Affiliation:
F. Hoffman-La Roche Ltd, Basel, Switzerland
Rolf Kettler
Affiliation:
F. Hoffman-La Roche Ltd, Basel, Switzerland
Hans H. Keller
Affiliation:
F. Hoffman-La Roche Ltd, Basel, Switzerland
Willy P. Burkard
Affiliation:
F. Hoffman-La Roche Ltd, Basel, Switzerland
Get access Rights & Permissions [Opens in a new window]

Abstract

The novel antidepressant, moclobemide, is a reversible inhibitor of monoamine oxidase (MAO) preferentially of monoamine oxidise-A (MAO-A); it emerged for study out of a series of lipid-lowering agents. In spite of its weak MAO-A inhibition in vitro, moclobemide is a potent inhibitor of MAO-A, in vivo; its in vivo activity is of short duration, in contrast to the extremely long-lasting inhibition, e.g. by tranylcypromine. Moclobemide only slightly potentiates the pressor effect of oral tyramine in freely moving rats, again in contrast to tranylcypromine; it is not anti-cholinergic and is free of hepatotoxicity. Published evidence on the preclinical pharmacology is reviewed.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 84 - 88
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bach, A.W.J., Lan, N.C., Johnson, D.L., et al (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proceedings of the National Academy of Sciences, USA, 85, 4934–4938.Google Scholar
Bieck, P.R. & Antonin, K.H. (1988) Oral tyramine pressor test and the safety of MAO inhibitor drugs. Comparison of brofaromine and tranylcypromine in healthy subjects. Journal of Clinical Pharmacology, 8, 237–245.Google Scholar
Burkard, W.P., Bonetti, E.P., Da Prada, M., et al (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology & Experimental Therapeutics, 248, 391–399.Google Scholar
Carruba, M.O., Picotti, G.P., Miodini, P., et al (1981) Blood sampling by chronic cannulation technique for reliable measurements of catecholamines and other hormones in plasma of conscious rats. Journal of Pharmacological Methods, 5, 292–303.Google Scholar
Da Prada, M., Kettler, R., Burkard, W., et al (1984) Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors (eds Tipton, K.F., Dostert, P. & Strolin Benedetti, M.). London: Academic Press.Google Scholar
Da Prada, M., Zürcher, G., Wüthrich, I., et al (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. Journal of Neuronal Transmission, 26 (Suppl.), 31–56.Google Scholar
Da Prada, M., Kettler, R., Keller, H.H., et al (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology & Experimental Therapeutics, 248, 401–414.Google Scholar
Denney, R.M. & Denney, C.B. (1985) An update of the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO-A and B. Pharmacology and Therapeutics, 30, 227–259.Google Scholar
Dostert, P. (1984) Myth and reality of the classical MAO inhibitors: reasons for seeking a new generation. In Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors (eds Tipton, K.F., Dostert, P. & Strolin Benedetti, M.). London: Academic Press.Google Scholar
Fowler, C.J. & Callingham, B.B. (1978) Substrate-selective activation of rat liver mitochondrial oxidase by oxygen. Biochemical Pharmacology, 27, 1995–2000.Google Scholar
Ghose, K. (1984) Tyramine pressor test: implications and limitations. Methods and Findings in Experimental and Clinical Pharmacology, 6, 455–464.Google Scholar
Goldman, L.S., Alexander, R.C. & Luchins, D.J. (1986) Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. Journal of Clinical Psychiatry, 47, 225–229.Google Scholar
Johnston, J.P. (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochemical Pharmacology, 17, 1285–1297.Google Scholar
Keller, H.H., Kettler, R., Keller, G., et al (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16–6491. Naunyn-Schmiedeberg's Archives of Pharmacology, 335, 12–20.Google Scholar
Korn, A., Da Prada, M., Raffesberg, W., et al (1988a) ‘Cheese effect’ in man: some studies with moclobemide, a new monoamine oxidase inhibitor. Journal of Neural Transmission, 26 (Suppl.), 57–71.Google Scholar
Korn, A., Da Prada, M., Raffesberg, W., et al (1988b) The effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. Journal of Cardiovascular Pharmacology, 11, 17–23.CrossRefGoogle ScholarPubMed
Schläppi, B. (1985) The lack of hepatotoxicity in the rat with the new and reversible MAO-A inhibitor moclobemide in contrast to iproniazid. Drug Research, 35, 800–803.Google Scholar
Simpson, G.M. & White, K. (1984) Tyramine studies and the safety of MAOI drugs. Journal of Clinical Psychiatry, 45, 59–61.Google Scholar
Suzuki, O., Katsumata, Y. & Masukazu, O. (1982) Substrate specificity of the type A and B monoamine oxidase. In Monoamine Oxidase: Basic and Clinical Frontiers (eds Kumijo, K., Usdin, E. & Nagatsu, T.). Amsterdam: Excerpta Medica.Google Scholar
Tiller, J.W.G., Maguire, K.P. & Davies, B.M. (1987) Tyramine pressor response with moclobemide, a reversible monoamine oxidase inhibitor. Psychiatry Research, 22, 213–220.Google Scholar
Timbell, J.A. (1979) The role of metabolism in the hepatotoxicity of isoniazid and iproniazid. Drug Metabolism Reviews, 10, 125–147.Google Scholar
Yang, H.-Y. & Neff, N.H. (1974) The monoamine oxidase of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. Journal of Pharmacology & Experimental Therapeutics, 189, 733–740.Google Scholar
Youdim, M.B.H., Banerjee, D.K. & Pollard, H.B. (1984) Isolated chromaffin cells from adrenal medulla contain monoamine oxidase, B. Science, 224, 619–621.CrossRefGoogle ScholarPubMed
Zeller, E.A. (1938) Über den enzymatischen Abbau von Histamin und Diaminen. Helvetica Chimica Acta, 21, 880–890.Google Scholar
Zeller, E.A., Barsky, J., Berman, E.R., et al (1952) Action of isonicotinic acid hydrazides and related compounds on enzymes involved in the autonomic nervous system. Journal of Pharmacology & Experimental Therapeutics, 106, 426–428.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.